FBRX

Forte Biosciences stock hits 52-week high at 76.69 USD

The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX)

Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion

Stocks making the biggest moves midday: ASML, SK Hynix, SAP, Forte Bio, Brown-Forman & more

argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX)

TD Cowen downgrades Forte Biosciences stock rating on Argenx deal

Forte Biosciences stock surges 39% on argenx acquisition deal

Why is Forte Biosciences stock surging nearly 40% today?

argenx to acquire Forte Biosciences for $2.2 billion in cash

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

Forte Biosciences stock hits 52-week high at 52.75 USD

Barclays initiates Forte Biosciences stock with overweight rating

Forte Biosciences stock hits 52-week high at $45.39

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - Slideshow (NASDAQ:FBRX) 2026-07-13